Organization
Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC
12 abstracts
Abstract
Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,
Abstract
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.Org: Roswell Park Comprehensive Cancer Center, University of California, San Diego Center for Advanced Laboratory Medicine, Moores Cancer Center, UC San Diego Health, Dartmouth Cancer Center, Lebanon, NH, Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,
Abstract
Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Buffalo, NY, Durham, NC, Burlington, NC,
Abstract
Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
Comparison of immune microenvironment between primary and metastatic breast tumors.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, OmniSeq (Labcorp), Roswell Park Comprehensive Cancer Center, OmniSeq, Inc., Personal Genome Diagnostics (Labcorp),
Abstract
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, OmniSeq (Labcorp), Duke University Medical Center, Duke Cancer Institute, OmniSeq, Inc.,
Abstract
Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Durham, NC,
Abstract
Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts.Org: ConcertAI, Bengaluru, Karnataka, Indiana University – Purdue University Indianapolis, Labcorp Drug Development Inc., Princeton, NJ,
Abstract
TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.Org: OmniSeq Inc. (Labcorp), Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.Org: ConcertAI, Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Labcorp Drug Development Inc., Princeton, NJ,
Abstract
Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, Research Triangle Park, NC,
Abstract
LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.Org: OmniSeq (Labcorp), OmniSeq Inc. (Labcorp), Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,